When my mom passed away at 62 years old six weeks after being diagnosed with a disease I’d never heard of before, it sent me searching for answers. NASH is still widely unknown and the etiology is not well understood. Yes, it is largely linked to obesity, but there are many other risk factors that seem to be playing a role. One such factor that I discovered last year was the link between hypothyroidism and NASH, which my mom had for decades.
Recently I have been working on some projects on how the liver works, and found myself intrigued when writing about the function of the gallbladder. For those that are unaware, its main function is storing bile to be used in the digestion of fats. As I wrote about it, alarm bells began ringing in my head. NASH is the end stage of fatty liver disease, caused by an excess buildup of fat in the liver.
Gallbladder surgery (known as cholecystectomy) is one of the most common surgical procedures in the world, with over 600,000 procedures performed annually in the USA. It is considered completely safe with no long-term negative effects. My mom had her gallbladder removed years ago after suffering gallstones, as is the standard medically recommended procedure. I wondered if there was any studies on possible links between it and NASH, and began searching.
One of the most difficult challenges with NASH is that it is so difficult to diagnose. While many Biotech companies are working hard to develop a cure for NASH, some are also busy developing new innovative methods to detect NASH without requiring an invasive liver biopsy.
Genfit is one of the few companies due to release Phase 3 trials of NASH treatments in 2019. Not content with focusing merely on a cure, they are also nearing completion of trials on a new blood test for earlier detection of NASH. They have just recently announced a partnership with LabCorp, which will allow them access to a much wider audience for the clinical research required to validate the new test.
2018 was a big year for those trying to raise awareness of NASH, as well as those developing treatments and diagnostic methods. The first International NASH Day was held, a day of action with events in over a dozen cities on four continents.
2019 is already looking to be a major year for progress in the fight against NASH. Recently, Goldman Sachs declared that 2019 will be “The Year of NASH” based on the fact that several BioTech companies are expected to release late-stage trial results of promising treatments.
Tonight I’m attending the ALF Honors Gala in my capacity as a Board Member and the chair of the Associate Board for the Greater New York Division. The Gala is an annual fundraiser that honors influential professionals, physicians, and business leaders in our community.
It also just happens to be Giving Tuesday! Here are some ways you can show your support:
Bid on one of our GNY Honors Gala auction items. With over 70 items to choose from, there is something for everyone! Click here to view all items.
Tony is a NASH transplant survivor and the founder of the NASH Education Corporation, a Pittsburgh-based non-profit focusing on increasing awareness and providing educational materials for NASH. I’ve been wanting to write about patients living with NASH for quite some time and Tony was generous enough to agree to an interview for a profile piece, the first ever on NASH AWARE.
A new study from New York Presbyterian Hospital has some eyebrow-raising findings. We already know that drinking coffee is good for the liver, but you would expect to find less evidence of a positive relationship with alcohol. Yes, there have been plenty of studies that show a glass of wine can be good for you, but never one that highlighted an actual positive link.
My mother passed away suddenly four years ago this month after a short battle with late-stage NASH. Which is impossible, but somehow true. Just a few days before being diagnosed with NASH she was celebrating with my wife and I at a housewarming party at the Shore. A picture of her from that party occupies a prominent place on our fridge; the last picture of her before our lives were all changed forever.
I lost my mother suddenly to late-stage NASH when she was only 62 years old. The search for answers and meaning has led me to working with the American Liver Foundation and starting this blog. One thing that has become increasingly clear to me was that my mom’s decades of hypothyroidism could have been a major cause of her progression to NASH. Now, a new meta-study examining 18 years of data has concluded that those patients with primary hypothyroidism are at a 42% increased risk for developing NAFLD, the precursor to NASH. Continue reading “The Thyroid’s link to NASH”→